|Title:||Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation||Authors:||Chen Y.C.
|Issue Date:||2012||Journal Volume:||44||Journal Issue:||4||Start page/Pages:||910-912||Source:||Transplantation Proceedings||Abstract:||
Objective: Hepatitis B virus (HBV) infection is hyperendemic in Taiwan. We have reported the outcome of (1) recipients with hepatitis B surface antigen (HBsAg)-positive; HBsAg-negative recipients who receive donor hearts from HBsAg-positive donors; and treatment with lamivudine of hepatitis B flare-ups after heart transplantation, using case numbers that range from 100 to 200. Methods: From July 1987 to May 2011, all 412 orthotopic heart transplant recipients and donors underwent routine preoperative screening for hepatitis B virus markers and liver function parameters. Lamivudine was prescribed prophylactically for recipients with elevated serum enzyme levels or an HBV DNA virus load before transplantation, or when there was evidence of hepatitis B flare-up after transplantation. Postoperative HBV markers and liver function parameters were collected over a mean follow-up time of 7.8 years. Results: Thirty-four recipients were HBsAg-positive before heart transplantation, and 23 experiencing HBV reactivation upon follow-up requiring lamivudine treatment. Clinical responses were achieved in all of them: 15 were complete and two, slow partial responses. Twenty-six recipients with an HBV na?ve status at the time of heart transplantation, and three patients received donor hearts from an HBsAg-positive donor under perioperative hepatitis B immunoglobulin prophylaxis. HBV infection was successfully prevented in two patients, but the other one contracted HBV hepatitis, which was successfully treated with lamivudine. Conclusions: HBV reactivation after the heart transplantation was common but usually well controlled with lamivudine treatment. Although posttransplantation liver function deteriorated for a period, there was no HBV infection-related morbidity or mortality. Perioperative hepatitis B immunoglobulin prophylaxis can successfully prevent HBV na?ve recipients from infection in some cases, but HBsAg-positive donors should only be considered in high risk situations. ? 2012 Elsevier Inc.
|ISSN:||0041-1345||DOI:||10.1016/j.transproceed.2012.03.040||metadata.dc.subject.other:||hepatitis B antibody; hepatitis B surface antigen; lamivudine; virus DNA; adult; conference paper; controlled study; disease marker; donor; female; follow up; health center; heart transplantation; hepatitis B; high risk patient; human; liver function; major clinical study; male; morbidity; mortality; nonhuman; outcome assessment; postoperative infection; preoperative evaluation; priority journal; treatment response; virus load; virus reactivation; Adult; Alanine Transaminase; Antiviral Agents; Biological Markers; DNA, Viral; Donor Selection; Female; Heart Failure; Heart Transplantation; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Retrospective Studies; Taiwan; Time Factors; Treatment Outcome; Viral Load; Virus Activation; Young Adult
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.